CD8A and neoplasm: Our previous study demonstrated that the PEK protein vaccine is able to generate potent antigen-specific immunity, including antigen-specific CD8+ and CD4+ T cell precursors, antigen-specific Abs, and anti-tumor effects to control micro-metastatic tumor lesions in a pulmonary metastatic model [20].